Impotence
impotence
Impotence
Impotence (Erectile Dysfunction) is the inability to initiate and maintain an erection. This disease must be very costly for married couples. So here are some informations about Impotence.
CAUSE
Impotence is usually the result of:
abnormalities of blood vessels
neurological disorders
Drugs
Abnormalities of the penis
psychological problems that affect sexual arousal.
The cause of the physical are more common in elderly men, while psychological problems are more common in younger men. Increasing age of a man, the impotence becoming more frequent, although impotence is Read the story »
Save Your Body From Cancer
Researchers are also optimistic Sorafenib therapy may be more beneficial for patients suffering from various cancers that are difficult to handle.
The absence of typical symptoms at the early stages of development of liver cancer resulted in most patients are diagnosed at an advanced stage. After the discovery of Sorafenib, the first systemic treatment approved for liver cancer patients get new hope, because the systemic therapy has proven successful in increasing patient life expectancy.
Sorafenib is classified into a new class of cancer treatment created to suppress tumor growth by inhibiting two types (enzymes) needed for the development of cancer cells and blood supply.
In a clinical trial involving 602 liver cancer patients, patients receiving these drugs to live on average for 10.7 months. While patients in the control group who received the placebo on average for 7.9 months of life. Sorafenib is currently also being tested as a potential therapy also for several other cancer types.
World Health Organization data unknown number of new cancer patients in the world would jump from 10 million in 2000 to 15 million by 2020. In Asia Pacific alone recorded nearly 3.5 million cases of cancer in 2002.
“In a situation where the disease no longer be cured, the cancer treatment is focused on increasing lifespan, maintaining, and improving quality of life as long as possible, by running the therapies that have been clinically proven,” said Dr. Agus S Waspodo, SpPD, KGEH from Dharmais Cancer Hospital, Friday, (20/11).
This step begins with the development of therapeutic targets does that prevent the growth and spread of cancer, by inhibiting a specific molecule that helps the growth and development of cancer.
Targeted therapy helps patients to tolerate systemic therapy and improve the control of symptoms. Although not a total cure, but this approach can slow, stop, or in some cases reduce the development of cancer so that patients can control their cancer to long term.
“The prognosis for liver cancer is often delayed because the disease shows no specific symptoms until the cancer grows to an advanced stage. In fact, approximately 80% of patients with (HCC) – type of liver cancer is most common – usually diagnosed at advanced stage and a medium, “explains Dr. Agus S Waspodo further.
At this stage, he said, operating as the most effective method of treatment of liver cancer can not be done. Therefore, it is important to have effective treatment options that can help patients deal with illness at different stages.
Based on clinical trials SHARP (Sorafenib HCC Assessment randomized Protocol), Sorafenib was successful in increasing survival of patients with advanced stage liver cancer to 44% compared with placebo.
Further studies in patients with HCC in the Asia Pacific region also confirmed the effectiveness of Sorafenib in the broader population of patients with HCC.
Based on the mechanism antiangiogenik and researchers are now running several clinical trials to determine the effectiveness of Sorafenib in combination or adjuvant therapy in the treatment of early stage HCC, which means that Sorafenib could bring benefits to many more patients around the stage liver cancer.
Sorafenib is also indicated for therapy (RCC) advanced stage, type of kidney cancer is most commonly found in adults. RCC tumors are considered as the most difficult to handle, because conventional anticancer therapies such as chemotherapy and radiotherapy have almost no effectiveness in the RCC.
The researchers are currently evaluating the potential of Sorafenib in the treatment various cancers, including thyroid cancer, lung cancer, acute, and breast cancer. Results from two phase III studies of lung cancer is expected to come out in 2010.
Comments
No Comments
Leave a reply